Regulatory Affairs Syndicator

Washington: A study conducted by German researchers contradicts a warning issued by the US Food and Drug Administration in October 2005, stating that exposure to paroxetine, a common anti-depressant, during the first three months of pregnancy could increase the risk of major congenital abnormalities, especially cardiovascular problems.